Thalidomide-CH2CONH-C2-COOH

Background Introduction

Thalidomide-CH2CONH-C2-COOH is a specialized E3 ligase ligand-linker conjugate designed for use in the construction of PROTACs (Proteolysis Targeting Chimeras). It is derived from thalidomide, a well-known ligand for the cereblon (CRBN) E3 ubiquitin ligase. The unique structure of this molecule, featuring a thalidomide moiety joined to a carboxylic acid via a stable linker, facilitates efficient and versatile PROTAC synthesis, enabling targeted protein degradation in both research and drug discovery applications.

Mechanism

Thalidomide-CH2CONH-C2-COOH functions by recruiting the CRBN E3 ubiquitin ligase through the thalidomide ligand component. The linker chain terminates in a carboxyl group, which allows easy conjugation to a target protein ligand (warhead) via amide coupling to create bifunctional molecules. When incorporated into a PROTAC, this conjugate acts by bringing a target protein into proximity with the E3 ligase, triggering ubiquitination and subsequent proteasomal degradation of the target protein. This mechanism provides a powerful alternative to traditional inhibition, offering the ability to eliminate disease-causing proteins from cells.

Applications

Thalidomide-CH2CONH-C2-COOH is widely used in the development of next-generation PROTACs for targeted protein degradation. Its applications include research on degradation of oncogenic or pathogenic proteins, exploration of undruggable targets, and evaluation of new therapeutic approaches in cancer, neurodegenerative diseases, and immunology. The product is ideal for medicinal chemistry workflows, facilitating the synthesis of custom PROTAC molecules and accelerating the lead optimization process in the drug discovery pipeline. It is also valuable for academic research focused on understanding the biology and pharmacology of targeted protein degradation.

• Carboxylic acid functionality enables versatile coupling with target ligands for customizable PROTAC design.
• Thalidomide-based structure specifically recruits CRBN E3 ligase, ensuring efficient and selective target protein degradation.

The Thalidomide-CH2CONH-C2-COOH E3 Ligase Ligand-Linker Conjugate plays a pivotal role in PROTACs by facilitating targeted protein degradation through its unique structural components. This molecule integrates a thalidomide-based ligand with a versatile linker, optimizing the conjugate's efficiency in binding and degrading specific proteins. The following provides a detailed description of this molecule.

Linker: The linker in this molecule is characterized by its short, flexible structure, consisting of a two-carbon chain (C2) that provides optimal spacing between the ligand and the reactive site. This flexibility aids in efficient molecular interactions and ensures the cleavability necessary for effective protein degradation.

Ligand: The ligand is derived from thalidomide, a well-known cereblon (CRBN) binder, with structural characteristics that enhance binding affinity and specificity. Its incorporation into the conjugate ensures effective recruitment of the E3 ubiquitin ligase complex, crucial for initiating proteasomal degradation of the target protein.

Reactive Site: The reactive site features a carboxylic acid group (COOH) that facilitates coupling with the target protein ligand through amide bond formation. Recommended reaction types include amide coupling reactions, which are efficient and widely used in biochemical applications to ensure stable conjugate formation.

Recommended Target Protein Ligand: The recommended warhead for this conjugate is a small molecule with a nucleophilic amine group, which can form a stable amide bond with the reactive site. This warhead type is advantageous due to its compatibility with a wide range of target proteins, enabling diverse applications in studying protein function and degradation pathways in cellular models.